Generic Name |
Brand Name |
Breast cancer type |
Breast cancer stage |
Where in the drug approval process is this treatment |
Atezolizumab |
Tecentriq |
Triple Negative |
Stage IV (metastatic) |
Health Canada - Approved |
Capecitabine |
Xeloda; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Carboplatin |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Cisplatin |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Cyclophosphamide |
Procytox; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Docetaxel |
Taxotere; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Doxorubicin |
Adriamycin; Myocet; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Epirubicin |
Pharmorubicin; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Eribulin |
Halaven |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Fluorouracil |
Actikerall; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Gemcitabine |
Gemzar; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Methotrexate |
Metoject; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Mitoxantrone |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Olaparib |
Lynparza |
HR+, HER2-, Triple Negative, BRCA |
Stage IV (metastatic) |
Health Canada - Approved |
Olaparib |
Lynparza |
HR+, HER2-, Triple Negative, BRCA |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
Paclitaxel |
Taxol; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Paclitaxel-nab |
Abraxane |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Pegylated Liposomal Doxorubicin |
Caelyx |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Health Canada - Approved |
Pembrolizumab |
Keytruda |
Triple Negative |
Stage IV (metastatic) |
PCPA - Approved; Provincial Review Ongoing |
Pembrolizumab |
Keytruda |
Triple Negative |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
Sacituzumab govitecan |
Trodelvy |
Triple Negative |
Stage IV (metastatic) |
PCPA - Approved; Provincial Review Ongoing |
Temozolomide |
Temodal; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Vinorelbine |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |